In COVID-19 clinical update #96, Daniel Griffin reviews Omicron in South Africa, rapid antigen tests, viral coinfections, isolation and quarantine, saliva preferred for Omicron, risk factors for severe disease in vaccinated, Paxlovid dosing, and long COVID. Click arrow to playDownload TWiV 850 (58 MB .mp3, 48 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
TWiV explores the impact of the intestinal virome on seroconversion after rotavirus vaccination, and implications of the ability of the SARS-CoV-2 beta variant to infect wild-type laboratory mice. Click arrow to playDownload TWiV 846 (61 MB .mp3, 102 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients. Hosts: Daniel Griffin and Vincent Racaniello Click arrow to playDownload TWiV 845 (58 MB .mp3, 48 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show …
TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin Read More »
TWiV provides an update on immunity to Omicron, results of a randomized controlled trial of face masks, and a study of correlates of protection against respiratory syncytial virus infection in the upper and lower respiratory tract of nonhuman primates. Click arrow to playDownload TWiV 841 (63 MB .mp3, 105 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show notes at microbe.tv/twiv
In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long …
TWiV 840: COVID-19 clinical update #92 with Dr. Daniel Griffin Read More »
It will be some time before a substantial fraction of the human population is immunized to prevent COVID-19. In the meantime, widespread use of face masks can have an impact on disease, a conclusion suggested by results of a trial carried out in Bangladesh. WHO would not recommend the use of face masks until June …
